Deletion of IL-6 in a murine model of primary biliary cirrhosis leads to exacerbated autoimmune cholangitis and lymphomas

weici zhang,masanobu tsuda,guoxiang yang,koichi tsuneyama,guanghua rong,william m ridgway,aftab a ansari,richard a flavell,ross l coppel,zhexiong lian,m eric gershwin
DOI: https://doi.org/10.4049/jimmunol.186.supp.101.6
2011-01-01
Abstract:Autoimmune liver diseases are characterized by elevated serum levels of IL-6. We have previously reported the development of a PBC-like model in dnTGF-βRII mice engineered to express a dominant negative form of transforming growth factor β receptor (dnTGF-βRII, dnR) under the control of CD4 promoter. By producing a double construct, namely IL-6 deficient mice on the dnTGF-βRII background (dnTGFβRII IL-6-/- mice), we previously reported that such animals manifest improvement in their underlying inflammatory bowel disease but worsening of their biliary infiltrates. To further understand this model, we have studied dnTGFβRII IL-6-/- mice and, in particular, focused on the pathology over a longer period of observation of up to 9 months. Importantly, loss of the IL-6 gene, although it does improve underlying inflammatory bowel disease, dramatically increases lymphoid aggregation, elevates inflammatory liver cytokines and promotes the appearance of activated T cells in liver. Indeed, loss of the IL-6 gene results in lymphomatous lesions in liver, spleen and lung at 6-9 months of age in 7 of 22 male dnTGFβRII IL-6-/- mice. No lesions were found in control dnTGFβRII mice. These data further highlight the promiscuous role of IL-6 and suggest caution in the therapeutic use of anti-IL6R antibody in the treatment of patients with autoimmune disease.
What problem does this paper attempt to address?